Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure.

Heart failure is a clinical syndrome characterized by the inability of the heart to meet the circulatory demands of the body without requiring an increase in intracardiac pressures at rest or with exertion. Hemodynamic parameters can be measured via right heart catheterization, which has an integral role in the full spectrum of heart failure: from ambulatory patients to those in cardiogenic shock, as well as patients being considered for left ventricular device therapy and heart transplantation. Hemodynamic data are critical for prompt recognition of clinical deterioration, assessment of prognosis, and guidance of treatment decisions. This review is a field guide for hemodynamic assessment, troubleshooting, and interpretation for clinicians treating patients with heart failure.

Informations de copyright

Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Rajagopalan has served as a consultant for Abbott Laboratories. Dr Borlaug is supported by R01 HL128526, R01 HL162828, and U01 HL160226 from the National Heart, Lung, and Blood Institute and W81XWH2210245 from the United States Department of Defense, as well as research grant funding from AstraZeneca, Axon, Medtronic, Novo Nordisk, and Tenax Therapeutics, and has served as a consultant for Amgen, Aria, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Merck, Novo Nordisk, NGM, NXT, and VADovations, and is named inventor (US Patent number 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Dr Bailey has served as a consultant for OptumRx and Nordisk. Dr Eckman has served as a consultant for Daxor. Dr Hall has served as a consultant for Abbott Laboratories, Abiomed, Evaheart, CareDx, and Natera. Dr Ramani has served as a consultant for Merck and has received research grant funding from United Therapeutics and Janssen. Dr Khazanie has research grant support from the National Institutes of Health (K23 HL145122) and the University of Colorado’s Ludeman Family Center for Women’s Health Research. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.